Zena and Michael A. Wiener Cardiovascular Institute, The Mount Sinai School of Medicine, New York, New York, USA.
J Am Coll Cardiol. 2010 Nov 16;56(21):1752-9. doi: 10.1016/j.jacc.2010.05.050.
the aim of this study was to determine whether nitrogen-containing bisphosphonate (NCBP) therapy is associated with the prevalence of cardiovascular calcification.
cardiovascular calcification correlates with atherosclerotic disease burden. Experimental data suggest that NCBP might limit cardiovascular calcification, which has implications for disease prevention.
the relationship of NCBP use to the prevalence of aortic valve, aortic valve ring, mitral annulus, thoracic aorta, and coronary artery calcification (AVC, AVRC, MAC, TAC, and CAC, respectively) detected by computed tomography was assessed in 3,710 women within the MESA (Multi-Ethnic Study of Atherosclerosis) with regression modeling.
Analyses were age-stratified, because of a significant interaction between age and NCBP use (interaction p values: AVC p < 0.0001; AVRC p < 0.0001; MAC p = 0.002; TAC p < 0.0001; CAC p = 0.046). After adjusting for age; body mass index; demographic data; diabetes; smoking; blood pressure; cholesterol levels; and statin, hormone replacement, and renin-angiotensin inhibitor therapy, NCBP use was associated with a lower prevalence of cardiovascular calcification in women ≥ 65 years of age (prevalence ratio: AVC 0.68 [95% confidence interval (CI): 0.41 to 1.13]; AVRC 0.65 [95% CI: 0.51 to 0.84]; MAC 0.54 [95% CI: 0.33 to 0.93]; TAC 0.69 [95% CI: 0.54 to 0.88]; CAC 0.89 [95% CI: 0.78 to 1.02]), whereas calcification was more prevalent in NCBP users among the 2,181 women <65 years of age (AVC 4.00 [95% CI: 2.33 to 6.89]; AVRC 1.92 [95% CI: 1.42 to 2.61]; MAC 2.35 [95% CI: 1.12 to 4.84]; TAC 2.17 [95% CI: 1.49 to 3.15]; CAC 1.23 [95% CI: 0.97 to 1.57]).
among women in the diverse MESA cohort, NCBPs were associated with decreased prevalence of cardiovascular calcification in older subjects but more prevalent cardiovascular calcification in younger ones. Further study is warranted to clarify these age-dependent NCBP effects.
本研究旨在确定含氮双膦酸盐(NCBP)治疗是否与心血管钙化的发生率有关。
心血管钙化与动脉粥样硬化疾病负担相关。实验数据表明,NCBP 可能限制心血管钙化,这对疾病预防具有重要意义。
通过回归模型评估 3710 名女性(MESA 中的多民族动脉粥样硬化研究)中 NCBP 使用与主动脉瓣、主动脉瓣环、二尖瓣环、胸主动脉和冠状动脉钙化(AVC、AVRC、MAC、TAC 和 CAC,分别)的相关性,这些女性按年龄分层,因为年龄和 NCBP 使用之间存在显著的交互作用(交互 p 值:AVC p<0.0001;AVRC p<0.0001;MAC p=0.002;TAC p<0.0001;CAC p=0.046)。在调整年龄、体重指数、人口统计学数据、糖尿病、吸烟、血压、胆固醇水平和他汀类药物、激素替代和肾素-血管紧张素抑制剂治疗后,NCBP 使用与≥65 岁女性心血管钙化的发生率降低相关(患病率比:AVC 0.68[95%置信区间(CI):0.41 至 1.13];AVRC 0.65[95% CI:0.51 至 0.84];MAC 0.54[95% CI:0.33 至 0.93];TAC 0.69[95% CI:0.54 至 0.88];CAC 0.89[95% CI:0.78 至 1.02]),而在 2181 名<65 岁的 NCBP 使用者中,钙化更为常见(AVC 4.00[95% CI:2.33 至 6.89];AVRC 1.92[95% CI:1.42 至 2.61];MAC 2.35[95% CI:1.12 至 4.84];TAC 2.17[95% CI:1.49 至 3.15];CAC 1.23[95% CI:0.97 至 1.57])。
在 MESA 队列中的女性中,NCBP 与老年患者心血管钙化发生率降低相关,但与年轻患者心血管钙化发生率增加相关。需要进一步研究以阐明这些与年龄相关的 NCBP 作用。